Rimma Driscoll
Executive Vice President, Global Strategy, Portfolio Marketing, Business Development, Human Health and Platinum PerformanceZoetis
PharmaceuticalsView Profile →Head of Corporate Development · Biogen
Adam Keeney leads corporate development at Biogen, combining discovery research, pharmaceutical business development and prior experience as NodThera’s chief executive officer.
Last reviewed: Nov 2, 2026
Head of Corporate Development
Biogen
Last Reviewed: November 2, 2026
Adam Keeney leads corporate development at Biogen, combining discovery research, pharmaceutical business development and prior experience as NodThera’s chief executive officer.
Keeney began his industry career as a discovery scientist at Lundbeck. He subsequently moved into business development, working at Johnson & Johnson from 2004 to 2013 in roles with increasing responsibility.
From 2014 to 2018, he worked at Sanofi, with responsibility for all of Sanofi Genzyme’s business development activities. His remit covered early-stage and later-stage transactions across therapeutic areas and treatment modalities.
Keeney became chief executive officer of NodThera in 2018. He led the clinical-stage biotechnology company, whose research focused on chronic inflammation, until 2022. This added responsibility for running a biotech business to his earlier scientific and transaction experience.
In April 2023, Keeney joined Biogen as executive vice president and head of corporate development and became a member of its executive committee.
Keeney earned a B.Sc. with honors from the University of Leeds and a Ph.D. in neuropharmacology from the University of Nottingham.